HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial
In patients treated with HER2-based neoadjuvant therapy, quantitative analysis of the readily available pretreatment HER2/CEP17 ratio by FISH is predictive of pCR.
Authors
- Christine Deutschmann
- Michael Gnant (ORCID: https://orcid.org/0000-0003-1002-2118)
- Anup Choudhury (ORCID: https://orcid.org/0000-0003-0813-6036)
- Christine Brunner (ORCID: https://orcid.org/0000-0003-0296-3719)
- Franz König (ORCID: https://orcid.org/0000-0002-6893-3304)
- R Greil
- Sabine Danzinger (ORCID: https://orcid.org/0000-0002-4316-6399)
- Evandro de Azambuja (ORCID: https://orcid.org/0000-0001-9501-4509)
- Daniel Egle
- C Singer
- Serena Di Cosimo
- Christoph Suppan (ORCID: https://orcid.org/0000-0003-0284-3848)
- Stephanie Kacerovsky-Strobl
- Marija Balic
Institutions
- Université Libre de Bruxelles (BE)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- Paracelsus Medical University (AT)
- Institut Jules Bordet (BE)
- Novartis (India) (IN)
- Comprehensive Cancer Center Vienna (AT)
- Austrian Breast & Colorectal Cancer Study Group (AT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- The Breast
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1016/j.breast.2025.104679
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Associazione Italiana per la Ricerca sul Cancro